Adjuvant docetaxel for node-positive breast cancer M Martin, T Pienkowski, J Mackey, M Pawlicki, JP Guastalla, C Weaver, ... New England Journal of Medicine 352 (22), 2302-2313, 2005 | 1347 | 2005 |
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic … DW Miles, A Chan, LY Dirix, J Cortés, X Pivot, P Tomczak, T Delozier, ... Journal of clinical oncology 28 (20), 3239-3247, 2010 | 1090 | 2010 |
Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study JF Boileau, B Poirier, M Basik, CMB Holloway, L Gaboury, L Sideris, ... Journal of Clinical Oncology 33 (3), 258-264, 2015 | 822 | 2015 |
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 M Piccart, GN Hortobagyi, M Campone, KI Pritchard, F Lebrun, Y Ito, ... Annals of oncology 25 (12), 2357-2362, 2014 | 646 | 2014 |
Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature review J Lemieux, E Maunsell, L Provencher Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2008 | 521 | 2008 |
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion LS Rosen, DH Gordon, W Dugan Jr, P Major, PD Eisenberg, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 471 | 2004 |
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer E Grunfeld, JA Julian, G Pond, E Maunsell, D Coyle, A Folkes, AA Joy, ... Journal of Clinical Oncology 29 (36), 4755-4762, 2011 | 373 | 2011 |
NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and … L Fehrenbacher, RS Cecchini, CE Geyer Jr, P Rastogi, JP Costantino, ... Journal of Clinical Oncology 38 (5), 444-453, 2020 | 307 | 2020 |
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial JR Mackey, M Martin, T Pienkowski, J Rolski, JP Guastalla, A Sami, ... The Lancet Oncology 14 (1), 72-80, 2013 | 266 | 2013 |
Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial S Johnston, S Puhalla, D Wheatley, A Ring, P Barry, C Holcombe, ... Journal of Clinical Oncology 37 (3), 178-189, 2019 | 196 | 2019 |
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2 … W Eiermann, T Pienkowski, J Crown, S Sadeghi, M Martin, A Chan, ... Journal of clinical oncology 29 (29), 3877-3884, 2011 | 189 | 2011 |
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group JR Mackey, M Clemons, MA Côté, D Delgado, S Dent, A Paterson, ... Current Oncology 15 (1), 24, 2008 | 187 | 2008 |
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer DW Miles, SL De Haas, LY Dirix, G Romieu, A Chan, X Pivot, P Tomczak, ... British journal of cancer 108 (5), 1052-1060, 2013 | 183 | 2013 |
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial SM Swain, G Tang, CE Geyer Jr, P Rastogi, JN Atkins, PP Donnellan, ... Journal of clinical oncology 31 (26), 3197-3204, 2013 | 169 | 2013 |
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer M Trudeau, F Charbonneau, K Gelmon, K Laing, J Latreille, J Mackey, ... The lancet oncology 6 (11), 886-898, 2005 | 164 | 2005 |
Is clinical breast examination important for breast cancer detection? L Provencher, JC Hogue, C Desbiens, B Poirier, E Poirier, D Boudreau, ... Current Oncology 23 (4), 332-339, 2016 | 122 | 2016 |
Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab±bevacizumab in patients with HER2-positive, node-positive or high … DJ Slamon, SM Swain, M Buyse, M Martin, CE Geyer, YH Im, ... Cancer Research 73 (24_Supplement), S1-03-S1-03, 2013 | 117 | 2013 |
Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. GN Hortobagyi, MJ Piccart-Gebhart, HS Rugo, HA Burris, M Campone, ... Journal of Clinical Oncology 31 (18_suppl), LBA509-LBA509, 2013 | 112 | 2013 |
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer J Simard, M Dumont, AM Moisan, V Gaborieau, H Vézina, F Durocher, ... Journal of medical genetics 44 (2), 107-121, 2007 | 111 | 2007 |
Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial M Al-Akoum, E Maunsell, R Verreault, L Provencher, H Otis, S Dodin Menopause 16 (2), 307-314, 2009 | 97 | 2009 |